dallas semaglutide gastric intestinal obstruction law firm GLP-1 Multi-District Litigation semaglutide gastric intestinal obstruction lawyer – dallas semaglutide gastric intestinal obstruction

Semaglutide has been found to reduce the risk of cardiovascular disease, including heart attacks, strokes, and kidney disease in people with type 2 diabetes

More specifically, the FD&C Act requires that bulk drug substances used to compound must: comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding

Non-alcoholic fatty liver disease (NAFLD) affects an estimated 30% of the global population and is the most common cause of chronic liver disease

Conditions affecting clotting, such as thrombocytopenia or von Willebrand disease, also predispose to bruising

GLP-1 drugs are a class of medications that mimic the way the GLP-1 hormone works in the body